301 related articles for article (PubMed ID: 25391969)
1. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades.
Esen H; Erdi F; Kaya B; Feyzioglu B; Keskin F; Demir LS
J Neurooncol; 2015 Feb; 121(3):451-8. PubMed ID: 25391969
[TBL] [Abstract][Full Text] [Related]
2. High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression.
Esen H; Feyzioglu B; Erdi F; Keskin F; Kaya B; Demir LS
Brain Tumor Pathol; 2015 Jul; 32(3):195-201. PubMed ID: 25592259
[TBL] [Abstract][Full Text] [Related]
3. New Clues in the Malignant Progression of Glioblastoma: Can the Thioredoxin System Play a Role?
Erdi F; Kaya B; Esen H; Karatas Y; Findik S; Keskin F; Feyzioglu B; Kalkan E
Turk Neurosurg; 2018; 28(1):7-12. PubMed ID: 28345125
[TBL] [Abstract][Full Text] [Related]
4. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
[TBL] [Abstract][Full Text] [Related]
5. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
6. Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas.
Thotakura M; Tirumalasetti N; Krishna R
J Cancer Res Ther; 2014; 10(3):641-5. PubMed ID: 25313753
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of the RNA-binding motif protein 3 in human astrocytoma.
Zhang HT; Zhang ZW; Xue JH; Kong HB; Liu AJ; Li SC; Liu YX; Xu DG
Chin Med J (Engl); 2013; 126(10):1948-52. PubMed ID: 23673116
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival.
Vlodavsky E; Soustiel JF
J Neurooncol; 2007 Jan; 81(1):1-7. PubMed ID: 16868661
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers relating to malignant progression in Grade II astrocytoma.
Yue WY; Yu SH; Zhao SG; Chen ZP
J Neurosurg; 2009 Apr; 110(4):709-14. PubMed ID: 19025355
[TBL] [Abstract][Full Text] [Related]
10. Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors.
Jiang L; Huang CG; Lu YC; Luo C; Hu GH; Liu HM; Chen JX; Han HX
Brain Res; 2008 Mar; 1201():161-6. PubMed ID: 18331723
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas.
Ahmed S; Rashed H; Hegazy A; Mohamed AM; Elmesallamy W
Turk Patoloji Derg; 2016; 32(2):70-81. PubMed ID: 27136105
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between miR-218 and CDK6 expression and their biological impact on glioma cell proliferation and apoptosis].
Zhang JM; Sun CY; Yu SZ; Wang Q; An TL; Li YY; Kong YL; Wen YJ
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):454-9. PubMed ID: 22088371
[TBL] [Abstract][Full Text] [Related]
13. Real-time quantification of the proliferative state in astrocytomas.
Ricco R; Cimmino A; Renzulli G; Serio G; Lozupone A; Lettini T; Pece A; Giardina C; Delfino VP
Anal Quant Cytol Histol; 2000 Jun; 22(3):213-7. PubMed ID: 10872037
[TBL] [Abstract][Full Text] [Related]
14. Comparative transcriptomics reveals similarities and differences between astrocytoma grades.
Seifert M; Garbe M; Friedrich B; Mittelbronn M; Klink B
BMC Cancer; 2015 Dec; 15():952. PubMed ID: 26673168
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors.
Ralte AM; Sharma MC; Karak AK; Mehta VS; Sarkar C
Pathol Oncol Res; 2001; 7(4):267-78. PubMed ID: 11882906
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of dUTPase in intracranial tumors.
Romeike BF; Böckeler A; Kremmer E; Sommer P; Krick C; Grässer F
Pathol Res Pract; 2005; 201(11):727-32. PubMed ID: 16325515
[TBL] [Abstract][Full Text] [Related]
17. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67.
Deckert M; Reifenberger G; Wechsler W
J Cancer Res Clin Oncol; 1989; 115(2):179-88. PubMed ID: 2715168
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 immunostaining in astrocytomas: Association with histopathological grade - A South Indian study.
Shivaprasad NV; Satish S; Ravishankar S; Vimalambike MG
J Neurosci Rural Pract; 2016; 7(4):510-514. PubMed ID: 27695229
[TBL] [Abstract][Full Text] [Related]
19. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
20. EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas.
Tsai WC; Chen Y; Huang LC; Lee HS; Ma HI; Huang SM; Sytwu HK; Hueng DY
J Neurooncol; 2013 Sep; 114(3):281-90. PubMed ID: 23817808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
